07:00 Tue 16 Feb 2021
Avacta Group PLC - Results of Initial Evaluation of SARS-CoV-2 LFT
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Results of Initial Evaluation of SARS-CoV-2 Lateral Flow Antigen Test with Clinical Samples
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in
Avacta's SARS-CoV-2 rapid antigen test has been developed to identify infectious individuals so that they can isolate promptly and reduce the spread of COVID-19. A recent report from the Liverpool Covid SMART Pilot Study1 indicates that individuals with COVID-19 infection had a significant chance of infecting their contacts if they had a viral load measured by PCR, called the Ct value (cycle threshold value), of approximately 25 or lower. The Ct value indicates how many PCR cycles are required to amplify the viral RNA so that it can be detected and a lower Ct value indicates a higher viral load.
The initial evaluation of Avacta's lateral flow rapid antigen test with clinical samples has been carried out at two sites, one in EU and one in the
On the basis of these excellent initial data, the Company will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in
Dr
"I am delighted with the performance of the test with clinical samples which is extremely encouraging.
On the basis of these initial clinical studies, the lateral flow test shows very good sensitivity in the infectious range of viral loads including at the lower infectious loads with Ct values of 23-26 which compares very favourably with the data reported in the Liverpool Covid SMART Pilot Study report.
These data from the first clinical studies will allow us to quickly progress with confidence into the full clinical validation of the test, manufactured at scale, at our clinical trial sites in the
I look forward to updating the market on clinical and commercial progress in due course."
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
Disclaimer: The AffiDxTM SARS-Cov-2 rapid antigen test is not currently available for sale in
- Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc |
Tel: +44 (0) 844 414 0452 |
|
|
|
|
|
|
finnCap Ltd (Nominated Adviser and Joint Broker) |
Tel: +44 (0) 207 220 0500 |
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Broker) |
Tel: +44 (0) 207 710 7600 |
|
|
|
|
FTI Consulting (Financial Media and IR) |
Tel: +44 (0) 203 727 1000 |
|
|
|
|
Zyme Communications (Trade and Regional Media) |
Tel: +44 (0) 7787 502 947 |
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of
Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development activities are based in
Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Company is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDXTM SARS-CoV-2 Lateral Flow Rapid Antigen Test and a BAMSTM SARS-CoV-2 Assay in partnership with Adeptrix Inc.
Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Company is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Company's lead pre|CISIONTM prodrug, in patients with locally advanced or metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with Moderna Therapeutics Inc., a multi-target deal with LG Chem worth up to
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE